Slone Partners Places David Stern as Chief Executive Officer of Mirvie

Fertility industry leader brings more than 30 years of precision care experience to his new role

SOUTH RIDING, Va., Nov. 10, 2026 — Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, today announced the placement of David Stern as Chief Executive Officer (CEO) at Mirvie, a pregnancy health company whose proprietary Mirvie RNA Platform™ enables early risk detection of pregnancy complications.

Stern brings more than 30 years of women's health leadership to Mirvie. Most recently, he was CEO of Kindbody, a national fertility clinic network and family-building benefits provider. Prior to that he served as CEO of Boston IVF, one of the largest fertility center providers in the U.S. As CEO of Symbiomix Therapeutics, Stern took the company from development through the commercial launch of Solosec, a breakthrough treatment for bacterial vaginosis, and successfully led its 2017 acquisition by Lupin Pharmaceuticals. Earlier in his career, he expanded and led the global fertility franchise at Merck Serono.

"Maternal health is at an inflection point, and Mirvie is positioned to lead it," said Leslie Loveless, CEO and Managing Partner at Slone Partners. "David pairs three decades of women's health leadership with hands-on experience building commercial businesses, from product launch through a successful acquisition. We are proud to have partnered with the team at Mirvie to find the CEO who will bring the company's exciting technological innovations to the expectant mothers who need it."

"Founding and leading Mirvie has been the work of a lifetime, and I am delighted to pass the torch to David to accelerate and scale our commercial growth," said Mirvie co-founder Maneesh Jain, PhD, who will transition from CEO to Executive Vice Chair of the Board. "The Board and I are excited to partner with David as we work to change the trajectory of preterm birth and maternal health outcomes, which remain unacceptably poor for too many expectant mothers in America."

"Pregnancy is one of the last outdated frontiers of medicine that is still managed largely by one-size-fits-all guidelines," said Stern. "What Maneesh and the team have built is rare: molecular insight into the biology of each pregnancy, a clinically validated test, established payer coverage, and growing demand from clinicians and patients. I've watched precision tools transform outcomes and the patient experience in fertility care, and I believe the technologies we are pioneering at Mirvie can do the same for pregnancy. It's an honor to lead Mirvie into this next phase."

Stern holds a BA in Biology and Economics from Brandeis University and an MBA in International Marketing and Management from the F.W. Olin Graduate School of Business at Babson College.

SOURCE Slone Partners